# Debate prop_0624__glm-5-3-high__grok-4.7-high__s0__tpl_placement_active_20260813a

- topic_id: prop_0624
- proposition: Health systems should permit and reimburse AI-assisted clinical documentation and triage only if models meet publicly reported accuracy and bias benchmarks.
- model_pro: glm-5-3-high
- model_con: grok-4.7-high
- side_swap: False

## Turn 1: PRO Opening

- model: glm-5-3-high
- raw_words: 315
- clipped_words: 315
- claim_ids: [P1.1], [P1.2], [P1.3], [P1.4], [P1.5], [P1.6], [P1.7], [P1.8]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[P1.1] Health systems already demand evidence before they pay for drugs, devices, and procedures. Artificial intelligence in clinical documentation and triage should not be the first exception in modern medicine. The proposition asks only that AI tools clear the same basic bar we set for everything else: demonstrate, publicly and reproducibly, that they work and that they work for everyone.
[P1.2] The stakes are concrete. Documentation AI transcribes what clinicians say into the medical record; errors become wrong medications, wrong allergies, wrong histories. Triage AI decides who gets seen first; systematic error becomes delayed care. Both operate on the most vulnerable moments in a patient's life.
[P1.3] A scribe that mishears a dosage or a triage model that systematically under-prioritizes patients whose speech patterns or symptom descriptions differ from its training data is not an inconvenience—it is a harm delivered at scale, invisibly, and with institutional backing.
[P1.4] Why benchmarks specifically? Because "trust us, it works" is not evidence. Internal validation by vendors has a documented pattern of optimistic bias. Public reporting changes incentives: a model's performance on under-represented subgroups becomes a market fact, not a marketing claim.
[P1.5] This is exactly the mechanism that drove quality reporting for hospitals and plan performance—transparency created accountability, and accountability drove improvement. Health systems that pay without benchmarks are subsidizing an unaccountable experiment on their own patients.
[P1.6] Note what the proposition does not do. It does not ban anything. It does not require perfection. It says: if you want reimbursement—the single most powerful lever a health system holds—you must show your numbers.
[P1.7] Models that are genuinely accurate and equitable lose nothing. Models that cannot survive public scrutiny should not be in the revenue stream anyway.
[P1.8] The only real dispute is whether opaque deployment is good enough. Medicine answered that question decades ago, and the answer was no. AI is powerful, but power without measurement is a liability. Condition the money on the evidence.

## Turn 2: CON Opening

- model: grok-4.7-high
- raw_words: 306
- clipped_words: 306
- claim_ids: [C1.1], [C1.2], [C1.3], [C1.4], [C1.5], [C1.6], [C1.7], [C1.8]
- cited_claim_ids: [P1.6]
- missing_claim_id_refs: (none)

[C1.1] Public accuracy and bias benchmarks are not a clinical trial in disguise. For documentation and triage AI they are unstable, gameable, and often aimed at the wrong target. Making them the exclusive condition for permission and reimbursement does not raise the evidence bar. It installs a veto that can block safer care.
[C1.2] The drug-and-device analogy fails. A pill has a fixed molecule and a defined endpoint. A scribe or triage aid is a workflow around a clinician who edits the note or overrides the queue. A vendor's public score does not say whether the finished chart is safer or the waiting room is fairer once humans are in the loop.
[C1.3] Paying only for that score confuses a model card with a patient outcome.
[C1.4] Bias metrics sharpen the danger. Fairness definitions conflict: equal error rates and equal priority scores are different demands, and meeting one can worsen the other. A triage model pushed toward a published demographic target can delay a sicker patient because the benchmark, not the bedside, became the goal. Chase the public number and the missed failure grows — the mumbled dose, the atypical story, the clinic absent from the test set.
[C1.5] "Only if" is the harm. [P1.6] says this is not a ban. For every tool that has not cleared a public reporting regime, it is a ban on use and on payment. No clinically settled regime exists.
[C1.6] While systems wait, clinicians keep charting at midnight and triage stays a rushed guess, prolonging the very harms the rule was meant to stop.
[C1.7] Public leaderboards crown the wrong winners: a vendor publishes a flattering score, while a hospital auditing overrides and adverse events locally may be safer and still forbidden. That is a lockout dressed as transparency.
[C1.8] Demand monitoring, clinician review, and outcomes. Do not hand one published snapshot the power to veto care.

## Turn 3: PRO Rebuttal 1

- model: glm-5-3-high
- raw_words: 308
- clipped_words: 308
- claim_ids: [P2.1], [P2.2], [P2.3], [P2.4], [P2.5], [P2.6]
- cited_claim_ids: [C1.4], [C1.6], [C1.7], [C1.5]
- missing_claim_id_refs: (none)

[P2.1] My opponent's strongest move is the claim that a public benchmark is a snapshot, not an outcome. But that argues for better reporting, not for abandoning the gate. Nothing in the proposition forbids a hospital from auditing overrides and adverse events locally—indeed, public benchmarks make such audits easier, because the vendor's claims are on record to compare against. What the proposition forbids is paying for tools whose performance nobody outside the vendor has seen.
[P2.2] The fairness-conflict argument [C1.4] proves too much. Yes, equal error rates and equal score distributions can trade off against each other. That is precisely why public reporting of multiple subgroup metrics matters: it exposes the tradeoff instead of letting a vendor pick the flattering one. "Fairness is mathematically messy" is an argument against a single mandated fairness formula—which is not what the proposition requires—and for transparency about where the cracks are.
[P2.3] The alternative, private deployment, doesn't resolve the conflict; it hides it.
[P2.4] The "midnight charting" image [C1.6] is doing heavy lifting. The proposition conditions reimbursement, not emergency use. A system that believes a tool helps can use it; it simply cannot put it in the revenue stream until the numbers are public. And note what CON concedes: if the tool is genuinely good, publishing its performance costs the vendor nothing but competitive opacity.
[P2.5] That is the heart of this. [C1.7] warns that a hospital's local tool might be safer than a leaderboard star. Fine—then report its numbers too. Local excellence that cannot survive measurement is a conjecture, and patients should not be the test population for conjectures with institutional billing codes attached.
[P2.6] Finally, "no settled regime exists" [C1.5] is an argument for building one, exactly as medicine did for hospital quality reporting—also once "unsettled." The first draft of accountability is always imperfect. The answer was never to keep the money flowing in the dark.

## Turn 4: CON Rebuttal 1

- model: grok-4.7-high
- raw_words: 314
- clipped_words: 314
- claim_ids: [C2.1], [C2.2], [C2.3], [C2.4], [C2.5], [C2.6], [C2.7], [C2.8], [C2.9]
- cited_claim_ids: [P2.4], [P2.6], [P2.2], [P2.1], [P2.5]
- missing_claim_id_refs: (none)

[C2.1] [P2.4] rewrites the motion. It says a system may use a tool and merely not bill for it. The proposition says permit and reimburse only if the model meets public accuracy and bias benchmarks. Restore "permit," and the midnight chart is the cost of waiting for a regime [P2.6] concedes is unsettled.
[C2.2] Relabeling ordinary delay as "emergency use" does not turn a clinic night into an exception.
[C2.3] "Report more metrics" does not answer fairness. [P2.2] reads the proposition as disclosure. "Meet" is clearance. Equal error rates and equal priority scores conflict; a model cannot clear both.
[C2.4] Publishing the crack still leaves someone to decide which crack fails the tool. That decision, not the bedside, becomes the veto. Extra columns on a model card do not dissolve a pass-fail gate.
[C2.5] Rejecting that gate is not rejecting evidence. A hospital can audit overrides and adverse events; a payer can inspect validation under contract; the clinician already edits the note and overrides the queue. Those are eyes outside the vendor. [P2.1] equates "not on a leaderboard" with "nobody has seen it."
[C2.6] What the proposition adds is a published snapshot empowered to forbid a workflow even when the audited chart is safer.
[C2.7] Hospital quality reporting does not save the analogy. It disclosed outcomes and later adjusted payment. It did not bar treatment until a public score existed. Once money attached, those measures were gamed—status reclassification, selective documentation, teaching to the test.
[C2.8] Tie permission and reimbursement to a model card, and vendors will optimize the card. The mumbled dose stays off the published set.
[C2.9] [P2.5] calls unmeasured local excellence a conjecture. A flattering public score is a conjecture too: it describes a frozen test, not this clinic's patients after a human edits the output. If the tool is good, demand monitored use and outcome review. Do not let an unsettled benchmark decide who may use a tool at all.

## Turn 5: PRO Pressure Questions

- model: glm-5-3-high
- raw_words: 66
- clipped_words: 66
- claim_ids: [P3.1], [P3.2]
- cited_claim_ids: [C2.5], [C2.8]
- missing_claim_id_refs: (none)

[P3.1] Q1: You say a payer can inspect validation under contract [C2.5]. If that private inspection is trustworthy evidence, what exactly is lost by making it public—and who does the secrecy protect, other than the vendor?
[P3.2] Q2: You warn that public scores get gamed by "teaching to the test" [C2.8]. Why would a private audit or contract inspection be *less* gameable—since nobody outside can see the gaming?

## Turn 6: CON Pressure Questions

- model: grok-4.7-high
- raw_words: 65
- clipped_words: 65
- claim_ids: [C3.1], [C3.2]
- cited_claim_ids: [P2.4], [P2.2]
- missing_claim_id_refs: (none)

[C3.1] Q1: What language in the motion supports your claim [P2.4] that a system may use a model which has not met the public benchmarks, so long as it does not bill for it?
[C3.2] Q2: If the proposition does not mandate a single fairness formula [P2.2], what does it mean for a model to meet bias benchmarks when equal error rates and equal priority scores conflict?

## Turn 7: PRO Rebuttal 2

- model: glm-5-3-high
- raw_words: 318
- clipped_words: 318
- claim_ids: [P4.1], [P4.2], [P4.3], [P4.4], [P4.5], [P4.6], [P4.7]
- cited_claim_ids: [C2.1], [C2.3], [C2.5]
- missing_claim_id_refs: (none)

[P4.1] A1: Fair challenge on the text. "Permit and reimburse only if" does condition both. I'll stand on the motion as written: a system may not deploy an unbenchmarked model at all. But that makes my case stronger, not weaker.
[P4.2] The condition is one any working tool can satisfy—publish its numbers and clear them. It is a gate, not a wall. The "midnight charting" cost [C2.1] lasts exactly as long as a vendor refuses to disclose what its product does. We would never accept "keep the drug on the market while the manufacturer decides whether to run the trial" as compassionate.
[P4.3] The delay is chosen by whoever withholds the evidence.
[P4.4] A2: "Meet bias benchmarks" means clearing defined subgroup performance floors: accuracy, error rates, and calibration reported separately for the populations the tool serves. That is how bias evaluation actually works in practice—stratified performance, not a single fairness formula. CON's impossibility point [C2.3] lands only on parity-style criteria, where satisfying one mathematical definition of fairness breaks another. Subgroup floors don't collide that way: a model can be accurate for older patients and for younger ones simultaneously; when it can't, that is precisely the finding we need public before triage decisions rest on it.
[P4.5] CON's strongest technical argument dissolves once "benchmarks" means the plural, stratified reporting the word implies.
[P4.6] Zoom out: both questions expose the same pattern. CON reads the motion in its most brittle possible form—single fairness formula, permanent lockout, snapshot as god—then attacks that caricature. But every failure mode CON fears, gaming, teaching to the test, frozen test sets, is worsened by its own alternative. Private audits and contract inspections [C2.5] can be gamed with no external check at all; my pressure questions went unanswered on that.
[P4.7] The choice is not benchmarks versus vigilance. It is evidence everyone can see versus evidence a vendor controls. Medicine chose the first long ago. Condition the money—and the permission—on showing the numbers.

## Turn 8: CON Rebuttal 2

- model: grok-4.7-high
- raw_words: 322
- clipped_words: 322
- claim_ids: [C4.1], [C4.2], [C4.3], [C4.4], [C4.5], [C4.6], [C4.7]
- cited_claim_ids: [P2.1], [P4.1], [P4.3], [P2.6], [P4.2], [P4.4]
- missing_claim_id_refs: (none)

[C4.1] A1: What is lost is the difference between evidence and a license. A payer can inspect validation under contract, resample this clinic's charts, withhold the item bank, and stop payment when overrides show the workflow fails. Turn that number into a public benchmark the model must meet, and the score becomes the target; the veto travels to every site the test set never saw. Keeping the review from becoming that license protects the clinic the card never measured, and the hospital whose audited notes are safer—not only the vendor.
[C4.2] [P2.1] equates "not on a leaderboard" with "nobody has seen it."
[C4.3] A2: Private inspection is less gameable because the payer who bears the harm chooses unseen, rotating cases and judges the edited chart. Public clearance is more gameable because the hurdle is visible and permission depends on clearing it. Spectators ratify teaching to the test; they do not expose it. Seeing the flattering metric does not reveal the mumbled dose left off the set.
[C4.4] A contract audit can keep the items closed. A benchmark that must be publicly met cannot stay both public and clean. Outside the vendor is not the public.
[C4.5] That is why the motion still fails. [P4.1] now admits an unbenchmarked model may not be deployed at all. The midnight chart is not a vendor withholding a PDF [P4.3]; it is what "permit only if" does while [P2.6] concedes the regime is unsettled. This is not a drug awaiting a trial the maker may postpone [P4.2].
[C4.6] No settled benchmark exists to pass, and a clinician already edits the note. [P4.4] renames "meet" as subgroup floors so the fairness collision disappears. Floors are still a veto. Someone sets the cut, and thin slices cannot clear error and calibration together.
[C4.7] A scribe can reduce missed doses for older and younger patients and still fail a rare-group floor. Do not let an unsettled card decide who may chart, or who is seen first.

## Turn 9: PRO Closing

- model: glm-5-3-high
- raw_words: 205
- clipped_words: 205
- claim_ids: [P5.1], [P5.2], [P5.3], [P5.4], [P5.5]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[P5.1] The whole debate reduces to one question: when a tool shapes the medical record and the triage queue, who gets to see whether it works—the people it's used on, or the vendor selling it?
[P5.2] Everything else CON raised is decoration on that choice. Gaming? A closed contract audit is gameable by the same vendor with no spectator ever able to check. Fairness conflicts?
[P5.3] They bite a single parity formula, not stratified subgroup floors, and publishing multiple metrics exposes tradeoffs rather than hiding them. The midnight chart? The delay lasts exactly as long as disclosure is withheld—CON's alternative keeps that choice in the vendor's hands forever.
[P5.4] CON's deepest concession is this: it never disputes that unmeasured deployment is dangerous. It argues only that private inspection is enough. But medicine rejected the private version of that argument decades ago—secret validation, trust-the-manufacturer, pay first and find out later. Public reporting is how every other accountability regime in healthcare works, imperfections included, because imperfection in daylight beats opacity every time.
[P5.5] The proposition demands nothing heroic: publish your numbers, clear them, and the revenue flows. Only tools that cannot survive daylight lose. That is not a veto on care—it's the price of touching patients. Decide for evidence everyone can see.

## Turn 10: CON Closing

- model: grok-4.7-high
- raw_words: 190
- clipped_words: 190
- claim_ids: [C5.1], [C5.2], [C5.3], [C5.4], [C5.5], [C5.6], [C5.7]
- cited_claim_ids: [P5.1], [P4.1], [P2.6]
- missing_claim_id_refs: (none)

[C5.1] The motion does not ask who may see the numbers. It asks who may practice. [P5.1] answers the first and loses the second.
[C5.2] Permit and reimburse only if is a license, not a window. [P4.1] admits an unbenchmarked model may not be deployed at all. [P2.6] concedes the regime is unsettled. Together, permission waits on a score that does not yet exist.
[C5.3] That wait is the midnight chart, not a withheld PDF.
[C5.4] Meet finishes the loss. Disclosure lets a payer compare claims to overrides. Clearance lets a published snapshot forbid the workflow even when the edited chart is safer. Floors do not dissolve that veto.
[C5.5] Someone still sets the cut, and a rare-group floor can fail a scribe that already reduces missed doses.
[C5.6] Private review is not a gift to the vendor. The payer who bears the harm can resample this clinic, keep the items closed, and stop payment when the workflow fails. That is evidence without a traveling ban. Rejecting the license is not defending darkness.
[C5.7] Daylight was never the price. An unsettled pass-fail was. Do not let that card decide who may chart, or who is seen first.
